71
Participants
Start Date
March 31, 2005
Primary Completion Date
October 31, 2009
Study Completion Date
January 31, 2012
Torisel
60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
Pfizer Investigational Site, New York
Pfizer Investigational Site, New York
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Greenville
Pfizer Investigational Site, Birmingham
Pfizer Investigational Site, Indianapolis
Pfizer Investigational Site, Münster
Pfizer Investigational Site, Chicago
Pfizer Investigational Site, Paris
Pfizer Investigational Site, Houston
Pfizer Investigational Site, San Francisco
Pfizer Investigational Site, Villejuif
Pfizer Investigational Site, Seattle
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Moscow
Pfizer Investigational Site, Saint Petersburg
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Houston
Pfizer Investigational Site, Calgary
Pfizer Investigational Site, Edmonton
Pfizer Investigational Site, Vancouver
Pfizer Investigational Site, Halifax
Pfizer Investigational Site, London
Pfizer Investigational Site, Toronto
Pfizer Investigational Site, Mexico City
Pfizer Investigational Site, Lublin
Pfizer Investigational Site, Lublin
Pfizer Investigational Site, Warsaw
Lead Sponsor
Pfizer
INDUSTRY